News

Award Supports Quest for New Medicines to Treat Lung Infections

Funding totaling £750,000 ($1,028,550) for a Strategic Research Centre (SRC) in the United Kingdom is expected to speed development of antibiotics to battle the lung infections that most cystic fibrosis (CF) patients experience. The four-year award from the Cystic Fibrosis Trust and the Cystic Fibrosis Foundation…

Study Unravels Patterns of Pseudomonas Evolution in Infections

Pseudomonas aeruginosa, the chief bacterial agent in cystic fibrosis (CF) lung infections, follows certain characteristic patterns of evolution, a new study reveals. “A long-standing lore in the cystic fibrosis field says that each patient’s infection tells a unique story, and that Pseudomonas evolves in unpredictable ways,” Jennifer Bomberger, PhD, said…

Global Genes, Diversity Coalition Team Up to Advance Health Equity

Global Genes has partnered with the Rare Disease Diversity Coalition (RDDC) to advance health equity for rare disease patients and caregivers in underrepresented communities of color. “For rare disease patients, there are many challenges — and for people of color with a rare disease, these challenges are compounded…

CF Trust, CF Foundation Launch Gene-editing Project

The U.K. Cystic Fibrosis Trust, in collaboration with the U.S. Cystic Fibrosis Foundation, is launching a new strategic research center (SRC) dedicated to studying gene editing as a potential treatment strategy for cystic fibrosis (CF). “Making gene editing a reality for people with CF will take the…

Liver Disease in CF Appears Linked to Problems in CFTR Protein

A unique interaction between CFTR — the protein defective in people with cystic fibrosis (CF) — and two pro-inflammatory proteins may explain why some CF patients develop liver disease, researchers reported. Their work suggests that the CFTR protein can act as an anchor, bringing certain proteins — including the pro-inflammatory…